AG-213 (25 μM, 50 μM, and 75 μM; 24 h, 48 h, and 96 h) increases wound closure time in human umbilical vein endothelial cell (HUVEC) monolayer.
AG-213 (100 μM; 1 h) interferes with HUVEC focal adhesion and stress fiber formation.
AG-213 (100 μM; 24 h) inhibits adherence-related tyrosine phosphorylation of pp125FAK in HUVEC.
AG-213 (10 μM; 24 h) inhibits tyrosine kinase activity, and (4.55-455 mM; 24-72 h) inhibits HT-29 cell viability doseand time-dependently.